

Acute Lung Injury/Acute Respiratory Distress Syndrome

F. H. Khan (Department of Anesthesia, The Aga Khan University Hospital, Karachi.)

Reports of pulmonary physiopathological insults following severe trauma resulting in respiratory failure are not new in medical literature^{1,2}. In 1967 Ashbaugh and colleagues described a syndrome of acute respiratory distress following a variety of precipitating conditions³. Severe hypoxemia, diffuse pulmonary infiltrates, poor lung compliance and absence of left heart failure characterize this condition. Ashbaugh et al⁴ subsequently named it as adult respiratory distress syndrome to differentiate it from infant respiratory distress syndrome. It was proposed at that time that both conditions manifest similar physiopathological changes. It was also referred to as “traumatic wet lung”, “congestive atelectasis”, or “Da Nang lung” and had a high mortality rate.

Since these initial reports, researchers focused their attention towards ARDS in order to find out the precipitating factors and therapeutic measures one can take to treat it. From these observations emerged this concept that different systemic conditions and variety of insults to the lung are associated with ARDS clinical syndrome⁵ and that it should be regarded as an extreme manifestation of a process called Acute Lung Injury (ALI). Murray quantified the severity of ARDS for determination of prognosis of patients suffering from this clinical syndrome. In 1988, he proposed an ALI score⁶ based on four components i.e., the extent of infiltration on patients chest x-ray, degree of hypoxemia, amount of positive end expiratory pressure (PEEP) used to oxygenate the patient and the patients respiratory system compliance when available.

Definitions and Diagnostic Criteria

In order to resolve the controversy about definitions, precipitating conditions and diagnostic criteria for ARDS, an American European Consensus conference (AECC) was held in 1994. This consensus conference⁷ report declared "the difficulty in determining the incidence and outcome of ARDS is largely due to the heterogeneity and lack of definitions for the underlying disease process [and] the lack of definition for ARDS". Despite controversy, the consensus conference ultimately recommended that "acute lung injury" (ALI) be defined as a syndrome of inflammation and increasing permeability. It is associated with a constellation of clinical, radiological and physiologic abnormalities that cannot be explained by, but may coexist with left atrial or pulmonary capillary hypertension and that ARDS be defined simply as a more severe form of ALI. The consensus conference also urged that there should be a return to the original term “acute” rather than “adult” in recognition that ARDS is not limited to adults only.

AECC members proposed the following diagnostic criteria for ALI and ARDS:

- a) Acute onset
- b) Bilateral chest radiographic infiltrates
- c) Pulmonary artery occlusion pressure of <18 mmHg or no evidence of left atrial hypertension and
- d) Impaired oxygenation regardless of PEEP administration with a PaO₂ / FiO₂ ratio of <300 mmHg for ALI and <200 mmHg for ARDS.

Although debate exists as to the utility of these criteria and the radiographic criteria of bilateral (but not diffuse) chest infiltrates for ALI and ARDS is nonspecific, these criteria are most widely accepted by clinical investigators.

Shuster⁸ in 1995 emphasized on the importance of linking structural changes with functional abnormalities; that results in ARDS. He defined ALI to be present when characteristic pathological

abnormalities in the lung result in deterioration of normal lung function, and ARDS to be a specific form of lung injury with diverse causes, characterized pathologically by diffuse alveolar damage and a breakdown in both the barrier and gas exchange functions of the lung, resulting in proteinaceous alveolar edema and hypoxemia.

Incidence of ALI and ARDS

The incidences of ALI and ARDS are not clear. A national institute of health panel in 1972 estimated the incidence of ARDS to be 150,000 cases per year in the United States⁹. Recent prospective studies have shown a much lower incidence of ARDS ranging from 1.5 to 8.4 cases per 100,000 populations per year^{10,11}. All of these studies were performed before the AECC definitions were developed. Data on the incidence of either ALI or ARDS using AECC criteria have not yet been published. In ongoing studies of ALI and ARDS at Harborview Medical Center, University of Washington based on AECC criteria the incidence of ARDS is 12.6/1000,000/year and the incidence of ALI and ARDS by AECC criteria is likely to be considerably higher than the recent prospective studies would indicate. However this remains to be confirmed.

Risk Factors for ALI and ARDS

Risk factors or etiologic factors for either conditions are associated with ARDS or markers that occur in conditions known to be associated with ARDS. These associated conditions are direct (primary) i.e. resulting in direct injury to the lung such as aspiration, lung infection, lung contusion or other inhalational injuries. Indirect (secondary) predisposing factors are sepsis, multiple trauma, burns, shock, acute pancreatitis and massive transfusion injuries to the lung through activation of systemic inflammation, presumably related in part to elevated cytokine levels and other biochemical and chemical mediators.

Pathogenesis

Regardless of whether the primary etiology originates within or outside the lung, a systemic inflammatory response accompanies and may determine the progression of ALI. Chemotaxis and activation of leukocytes lead to the release of cytotoxic free radicals and cytokines such as tumor necrosis factor and the interleukins. The expression of leukocyte adhesion molecules and proteases contribute to epithelial and endothelial injury¹². A number of homeostatic systems are activated: the complement and kinin system, the coagulation cascade, the cyclo-oxygenase and leukotrienes pathway and the NO- elevated cytokine levels and other biochemical and chemical mediators.

Pathogenesis

Regardless of whether the primary etiology originates within or outside the lung, a systemic inflammatory response accompanies and may determine the progression of ALI. Chemotaxis and activation of leukocytes lead to the release of cytotoxic free radicals and cytokines such as tumor necrosis factor and the interleukins. The expression of leukocyte adhesion molecules and proteases contribute to epithelial and endothelial injury¹². A number of homeostatic systems are activated: the complement and kinin system, the coagulation cascade, the cyclo-oxygenase and leukotrienes pathway and the NO-cyclic guanosine monophosphate pathway. The systemic inflammatory process contributing to acute lung injury is complex. These complex processes interact to cause increase in shunt fraction, decrease in pulmonary compliance, increase in airway resistance, ventilation perfusion imbalance and pulmonary hypertension.

Phases of ALI / ARDS

Initial Phase

During the first 3-5 days of respiratory failure, there is an increase in the permeability of the endothelial and epithelial barriers of the lung with accumulation of protein rich edema fluid in the interstitial and air spaces of the lung¹³. This results in severe defect in oxygenation, a reduction in lung compliance and bilateral pulmonary infiltrates¹⁴. Some of the studies have shown that during this phase there is either production of abnormal surfactant or inactivation of surfactant by the protein rich edema

fluid^{15,16}. The edema fluid contains a variable quantity of red blood cells, white blood cells, hyaline membranes, (which consists of albumin, immunoglobulin, fibrin, fibrinogen and other proteins)¹⁷. This has been given the name of diffuse alveolar damage. Some patients recover from this insult where as others pass into a sub-acute or chronic phase of lung injury¹⁸.

Sub-acute Phase

This phase, which develops 5-7 days after the onset of lung injury, is characterized physiologically by an increase in alveolar dead space, necessitating a high minute ventilation to achieve a normal or near normal PaCO₂. There is also a persistent oxygenation defect as well as decrease in the lung compliance.

There is evidence of interstitial fibrosis with proliferation of alveolar type 2 cells and both obstruction and destruction of portions of microcirculation of lungs¹⁹⁻²¹. During this phase there are usually persistently large unchanging bilateral infiltrates on chest X-ray.

Chronic Phase

When the patient survives these phases there is a gradual transition to a chronic phase of lung injury with persistently low lung compliance and a markedly elevated dead space fraction. There is pathological evidence of extensive pulmonary fibrosis with obliteration of normal alveolar architecture and progressive development of emphysematous region of the lungs including the development of discrete emphysematous bullae, which can be observed by CT Scan only²².

Management

The management of ARDS is complex. It consists of supportive management that supports the physiologic abnormalities and returns them towards normal but which has no fundamental effect on the underlying mechanism of lung injury, and that, which is definitive, i.e. which affects the mechanism of injury. A large number of management strategies have been proposed in the literature mostly involving animal models. Some of the management strategies that have been evaluated in humans over the last 10-15 years shall be reviewed here.

Ventilatory Management

Many new forms of mechanical ventilatory support for patients with ARDS have been proposed.

The goals of ventilatory management²³ in patients with ARDS are to:

Ensure appropriate oxygen delivery to vital organs along with sufficient CO₂ removal

Minimize oxygen toxicity

Recruit alveoli

Minimize high airway pressure

Prevent atelectasis

Use sedation and paralysis judiciously

In order to achieve the above-mentioned goals of ventilatory management, a number of ventilatory strategies have been proposed and these are:

Permissive Hypercapnia

Low tidal volume strategy has shown beneficial effects in patients with ALI/ARDS²⁴. Here the tidal volume is reduced to between 5-7 ml/kg of the body weight. The PaCO₂ is slowly allowed to rise giving the time to the body to compensate for this respiratory acidosis. It is suggested that pH as low as 7.15 or 7.2 may be well tolerated in the absence of significant cardiac or central nervous system abnormalities²⁵. One recent study in animal model has shown that therapeutic Hypercapnia protects against ALI²⁶.

Pressure Controlled Ventilation

In order to minimize the high airway pressure in patients with ALI/ARDS, pressure controlled ventilation is currently the most favoured mode used by intensivists all over the world. In the pressure control mode, the pre set time factors trigger gas flows that continues until a predetermined pressure is

achieved in the proximal airway. The pressure controlled mode provides very rapid initial flows that later on decelerate. The theoretical advantage of this rapid initial flow includes better gas mixing and improved patient synchrony. Assuming an adequate inspiratory time, the delivered tidal volume will be determined by the pre set airway pressure and the pulmonary compliance. Therefore if there is a significant decrease in the compliance of patients lung than the tidal volume delivery can decrease.

Inverse Ratio Ventilation

Inverse ratio ventilation is an alternative method of limiting excessive airway pressures. In inverse ratio ventilation the inspiratory time is prolonged thereby increasing mean airway pressure while maintaining peak airway pressures²⁷. Selecting an inspiratory / expiratory ratio greater than 1:1 may allow for recruitment of non compliant, surfactant deficient alveoli and more homogeneous gas delivery. The maximal benefit of inverse ventilation on gas exchange may take several hours to achieve, which supports the hypothesis that sustained inspiratory pressure is one mechanism of benefit with its use. Based on clinical experience it has been shown to improve gas exchange in patients with ARDS who failed to maintain oxygenation with conventional ventilation using PEEP²⁸.

However a recent randomized, cross over study failed to show any improvement with inverse ratio ventilation²⁹. As it has not been well studied and is uncomfortable for the patient requiring high dose of sedation or neuromuscular blockade, it is currently not recommended as the initial ventilatory approach in all patients with ALI/ARDS. However it can be considered in patients with refractory hypoxaemia requiring high FiO₂, or when the use of PEEP is associated with excessive peak air way pressures.

Positive end expiratory pressure (PEEP)

PEEP has a definite role in recruiting and stabilizing injured alveoli³⁰. This improves ventilation perfusion mismatch and lung compliance. Acute lung injury is a heterogeneous condition so PEEP applied to the patient may be appropriate in one region of the lung but may cause over distention in the other. It may be sub-optimal in the third region. It is therefore of paramount importance to select best PEEP in the patients with ARDS to avoid the deleterious effects. PEEP in the range of 5-15 cms H₂O has been found to provide a reasonable balance between these effects³¹. One can increase the PEEP above 15 cms H₂O, but this usually will result in over distention of already recruited alveoli. For this reason PEEP level >20 cms of H₂O or PEEP levels associated with plateau pressure of >35 cms of H₂O are generally avoided³².

Fluid Management

There has always been a controversy regarding optimal fluid management in patients with ARDS. This controversy revolves around which fluid to use and whether to use fluid or not. There are few who advocate keeping the patient with ARDS relatively dry either by diuretics or restricting fluids whereas others favor fluid administration to maintain DO₂, cardiovascular and renal function³³.

Those who favour fluid restriction base their arguments on theoretical, experimental and clinical data. Experimental studies have indicated that pulmonary functions and outcome are better in patients who achieve a negative fluid balance where as positive fluid balance results in worse outcome³⁴⁻³⁶.

Recommendations are to maintain a lower pulmonary artery wedge pressure by either restricting fluid or by using diuretics especially during the first few days of onset of ARDS³⁷. However at a later stage fluid restriction is of no benefit specially when fibrosis has occurred. One should be careful about aggravating renal function and to avoid problems from fluid restriction a pulmonary artery wedge pressure monitoring is essential³⁸.

Prone positioning

The infiltrates in the lungs of patients with ALL / ARDS are not evenly distributed therefore by changing the position of patient one can get improvement in gaseous exchange³⁹. If there is more involvement of one lung, then the lateral decubitus position may benefit the patient. The patient should be in a position in which the less diseased lung is dependent in order to match ventilation and

perfusion. Prone position to improve oxygenation in patients with ARDS has been proposed in many studies⁴⁰. The prone position is beneficial because it generates a transpulmonary pressure sufficient to exceed airway-opening pressure in dorsal lung regions where atelectasis, shunt and ventilation perfusion mismatch occurs⁴¹. This approach should be used only in centers experienced with it because of the problems and complications associated with prone position⁴². A randomized controlled trial which was done in 35 Italian intensive care units showed an improvement in oxygenation of 85% after 6 hours of prone positioning³⁹.

Nitric Oxide

Nitric oxide is a potent pulmonary vasodilator. When given by inhalation in small doses, it causes vasodilatation of ventilated areas. Blood is directed from the poorly or non-ventilated areas to better ventilated areas of lung and improvement in ventilation perfusion mismatch and reduction in intrapulmonary shunting occurs. The nitric oxide is blended with oxygen and administered to the patient in parts per million. The optimal dose of nitric oxide inhalational therapy is not determined but response may be patient specific or related to the severity of ARDS. Side effects of high concentration of nitric oxide are methemoglobinemia, acute pulmonary edema and acidemia but the likelihood of toxicity from prolonged inhalation of Nitric oxide (2-20 ppm) is minimal⁴³. There are published data that indicates that nitric oxide reduces pulmonary artery pressure and shunt. It also increases PaO₂/FiO₂ ratio without affecting cardiac output or systemic arterial pressure. However a recent randomized trial of 177 patients using 4 doses of nitric oxide failed to show any improvement in oxygenation or duration of mechanical ventilation⁴⁴. Other clinical trials in adults have failed to show any benefit on mortality or on mechanical ventilation requirements⁴⁵. Nitric oxide can be considered a rescue therapy in patient with ARDS refractory to conventional modes of ventilation and gas exchange support.

Corticosteroids

The ability of corticosteroids to attenuate host inflammatory response has provided the rationale for their use in ARDS. Large prospective studies in the mid 80s failed to demonstrate increased survival when high dose steroids were used in early phases of ARDS⁴⁶.

In refractory or late ARDS corticosteroids improve important physiological values. Criteria that investigators used for prescribing steroids for late ARDS were:

- No improvement for at least 72 hrs with maximum ventilatory support
- When no other therapeutic options were available
- Progressive respiratory failure with worsening lung injury score
- No evidence of active infection.

There has been only one prospective randomized trial⁴⁷ a pilot study of 24 patients, which suggests that this therapy may be beneficial corticosteroids may have an important role in patients with late ARDS⁴⁸. Large prospective trials are needed to determine specific target patient characteristic, timing of the start of therapy and optimal dosage and duration of therapy.

Surfactant Replacement Therapy

In ALI surfactant becomes dysfunctional because of altered composition and disruption of the continuity of the surfactant layer by pulmonary edema fluid and neutrophilic infiltration⁴⁹. Surfactant replacement therapy has been evaluated in the infant respiratory distress syndrome with recognized benefits⁵⁰.

Exogenous surfactant administration in adult human has been investigated in many studies that have shown trends towards increased survival but no difference in other measured parameters were noted⁵¹. A prospective, multicentre, double blind, randomized, placebo controlled study involving more than 700 patients with sepsis induced ARDS has failed to show any benefit of exogenous surfactant administration by continuous aerosol⁵². However one of the recently published study concluded that the pulmonary response to exogenous surfactant after mechanical ventilation is experimental. ALI is

improved when a ventilatory strategy with high PEEP is used⁵³.

Surfactant still may show promise in specific subgroups of ARDS, or may have a role in the treatment of patients with high risk of syndrome. Dosage, mode of delivery, timing of therapy and its use in combination with other agents are areas where it deserves prospective trials before final decisions can be made to eliminate it from the treatment options for ARDS.

Outcome

Factors associated with mortality include risk factors and age. Patients developing ARDS secondary to sepsis have a considerably higher mortality than most other common risk factors⁵⁴. Older patients greater than 65 years of age have an increased mortality rate⁵⁵.

The severity of ARDS at the time of first diagnosis as measured by oxygenation abnormality (PaO₂/FiO₂) has generally not been associated with differing outcomes. Krafft et al⁵⁶ in a meta analysis of 102 publications on ARDS found no correlation between PaO₂/FiO₂ and mortality. The most common cause of death in patients with ARDS is sepsis and multiple organ failure rather than hypoxia^{57,58}.

Conclusion

ALI/ARDS is a complex response of the lung to direct and indirect insults. Treatment of ALI/ ARDS is mainly supportive at the moment. Ventilatory management is the mainstay of supportive therapy and many new ventilatory strategies have been proposed. Attention has been turned to prevention of iatrogenic lung damage by use of pressure controlled ventilation and permissive hypercapnia, thus limiting the rise in peak airway pressure. For those with refractory hypoxaemia, inverse ratio ventilation, use of nitric oxide and prone position do offer some improvement in oxygenation. Most of the deaths in patients with ALI/ARDS is secondary to multiple organ failure. There is therefore a need to evolve strategies to prevent the development of non-pulmonary organ dysfunction in these patients.

References

1. Moon LJH, Pathological features following shock with delayed death. *Am. J Pathol.*, 1936; 12: 788-97.
2. Burford TH, Burbank B. Traumatic wet lung : observations on certain physiologic fundamental in thoracic trauma. *J. Thorac. Surg.*, 1945; 14 :415-24.
3. Ashbaugh DO, Bigelow DB, Petty TL, et al. Acute respiratory distress in adults. *Lancet.*, 1967; 2: 319-23.
4. Petty TL, Ashbaugh DO. The adult respiratory distress syndrome: clinical features, factors influencing prognosis and principles of management. *Chest.*, 1971; 60: 273-79.
5. Clowes GHA, Hirsch E, Williams L, et al. Septic lung and shock lung in man. *Ann. Surg.*, 1975; 181: 681-92.
6. Murray JF, Matthay MA, Lure JM, et al. An expanded definition of the adult respiratory distress syndrome. *Am. Rev. Respir. Dis.*, 1988; 138: 720-23.
7. Bernard OR, Artigas A, Brigham RL., et al. The American European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. *Am. J. Respir. Crit. Care Med.*, 1994; 149: 818-24.
8. Shuster PD. What is acute lung injury? What is ARDS? *Chest.*, 1995; 107:1721-26.
9. National Heart and Lung institute, National institutes of health. Respiratory distress syndromes: task force on problems, research approaches, needs. Washington, DC: US Government printing office, DHEW, 1979; (publication NO (NIH) 73-432: 165-180).

10. Villar 3, Slutsky AS. The incidence of the adult respiratory distress syndrome. *Am. Rev. Respir. Dis.*, 1989; 140: 814 -16.
11. Lewandowski K, Metz J, Deut Schmann C, et al. Incidence severity and mortality of acute respiratory failure in Berlin, Germany. *Am. J. Respir. Crit. Care Med.*, 1995; 151: 1121-25.
12. Lee WI, Diowney GP, Neutorplid activation and acture lung injury. *Curr Opinion Crit Care*, 2001; 7: 1-7.
13. Brigham KL, Meyrick B. Endotoxin and lung injury. *Am. Rev. Respir. Dis.*, 1986; 133: 913-27.
14. Lamy M, Fallat R.J, Koeniger E, et al. Pathological features and mechanisms of hypoxemia in adult respiratory distress syndrome. *Am. Rev. Respir. Dis.*, 1976; 114: 267-84.
15. Gregory Ti, Longmore WJ, Mosley MA, et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. *J. Clin. Invest.*, 1991; 88: 1976-81.
16. Hallman M, Spragg R, Harrel JH, et al. Evidence of lung surfactant abnormality in respiratory failure. *J. Clin. Invest.*, 1982; 70: 673-83,
17. Augliman RP, Gunther KL, Keeton DA, et al. Changes in the inflammatory response of' the lung during acute respiratory distress syndrome: prognostic indicators. *Am. 3. Rev. Resp. Crit. Care Med.*, 1996; 154: 76-81.
18. Matthay MA. Function of the alveolar epithelial barrier under pathological conditions. *Chest.*, 1994; 105: 675-745.
19. Zapol WM, Trelstad RL, Coffey 3W, et al, Pulmonary fibrosis in severe acute respiratory failure. *Am. Rev. Respir. Dis.*, 1979; 119: 547-54.
20. Fukuda Y, Ishizaki M, Masuda Y. et al!. The role of intra-alveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. *Am. J. Pathol.*, 1987; 126: 171-82.
21. Tamashefski JF, Davies Jr. P, Boggis C, et al. The pulmonary vascular lesions of the adult respiratory distress syndrome, *Am. J. Pathol.*, 1983; 112: 112-26.
22. Gattiononi L, Bombino M, Pelosi P, et al. Lung structure and fUnction in different stages of severe adult respiratory distress syndrome. *JAMA.*, 1994; 271: 1772-79.
23. American College of Chest Physician Consensus group. Mechanical Ventilation. *Chest*, 1993; 104: 1833-59.
24. Feihl F, Perret C. Permissive Hypercapnia. How permissive should we be? *Am. 3. Rcspr. Crit. Care Med.*, 1994; 150: 1722-37.
25. The acute respiratory distress syndrome network. Ventilation with lower tidal volume as compared with traditional volumes for acute lung injury and the acute respiratory distress syndrome. *N. Engi. 3. Med.*, 2000; 342 : 1301-8.
26. Gurevitch MJ, Van Dyke 3, Young ES. et al. Improved oxygenation and lower peak airway pressure in severe adult respiratory distress syndrome: treatment with inverse ratio ventilation. *Chest.*, 1986;89:211-3.
27. LafTey JG, Tanaka M, Engelbcrts D, et al!. Therapeutic Hyprcapnia reduces pulmonary and systemic injury following in vivo lung reperfusion. *Am. J. Rcspr. Crit. Care. Med.*, 2000; 162: 2021-2
28. Tharratt RS, Allen R.P, Albertson TE. Pressure controlled inverse ratio ventilation in severe adult respiratory failure. *Chest.*, 1988;94:755-62.
29. Mercat A, Titinga M, Anguel N. et al. inverse ratio ventilation (I/E = 2/I) in acute respiratory distress syndrome: a six - hour controlled study. *Am. J. Respir. Crit. Care. Med.*, 1997;155:1637-42.
30. American Association of Respiratory Care Consensus Group. Positive end expiratory pressure. *Respir. Care.*, 1998; 33: 419-527.
31. Gattioni LD, Andrea L, Petosi P, et al. Regional effects and mechanisms of positive end respiratory pressure in early respiratory distress syndrome. *JAMA*, 1993; 269: 2122-27.
32. Amato, M.B.P., Barbas, C.S.V., Medeiros, D.M., et al. Beneficial effects of the "open lung approach" with low distending pressures in acute respiratory distress syndrome: a prospective randomized study

- on mechanical ventilation. *Am. J. Respir. Crit. Care Med.*, 1995; 152: 1835-46.
33. Shuster, DP. Fluid management in ARDS: "Keep them Dry" or does it matter? *Intensive Care Med.*, 1995; 21: 101-3.
34. Shuster, DP. The case for and against fluid restriction and elusion pressure reduction in adult respiratory distress syndrome. *New Horiz.*, 1993; 1: 478-88.
35. Bone RC. Treatment of adult respiratory distress syndrome with diuretics, dialysis and positive end expiratory pressure. *Crit. Care Med.*, 1978; 6: 136-39.
36. Humphrey H, Hall 3, Sznajder 1, et al. Improved survival in ARDS patients associated with a reduction in pulmonary capillary wedge pressure. *Chest.*, 1990; 97:1176-80.
37. Martin GS, Fluid balnce and colloids osmotic pressure in acute respiratory failure emerging clinical evidence *Crit. Care.*, 2000; (4 suppl 2): 52 1-5.
38. Mitchell JP Schuller D, Calandrino FS, et al. Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization. *Am. Rev. Resp. Dis.*, 1992; 145: 990-98.
39. Douglas WW, Rehder K, Beynen FM, et al. Improved oxygenation in patients with acute respiratory failure: The prone position. *Am. Rev. Respir. Dis.*, 1977; 115:559-66.
40. Chatte G, Sab JM, Dubois 3M, et al. Prone position in mechanically ventilated patient with acute respiratory failure. *Am. J. Respir. Crit. Care Med.*, 1997; 155: 473-78.
41. Lamm WJE, Graham MM, Albert RK, Mechanism by which the prone position improves oxygenation in acute lung injury. *Am. J. Respir. Crit. Care Med.*, 1994; 150: 184-93.
42. Pelosi P, Caironi P, Taccone P, et al. Pathophysiology of prime positioning in the healthy lung and in AL! / ARDS. *Minerva Anesthesiol.*, 2001; 67: 238-47.
43. Bigatello I.M, Hurford WE, Kacmerx RM, et al. Prolonged inhalation of low concentration of Nitric oxide in patients with severe acute respiratory distress syndrome. *Anesthesiology*, 1994; 80: 761-70.
44. Dellinger RP, Zimmerman JL, Taylor RW, et al. Inhaled Nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase 11 trial, *Crit. Care Med.*, 1998; 26: 15-23.
45. Payer DM, Inhaled nitric oxide and acute lung injury *Clin, Chest Med.*, 2000; 21:519-29.
46. Luce JM, Montgomery AB, Marks i, et al. Ineffectiveness of high dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. *Am. Rev. Respir. Dis.*, 1988; 138:62 8.
47. Meduri GUS, Headley E, Golden S, et al. Methylprednisolone treatment (MPT) of late ARDS (abstracts). *Am. J. Resp. Crit. Care Med.*, 1997; 155:A391.
48. Bernard GR, Luce 3M, Sprung CL. et al, High dose corticosteroids in patients with the adult respiratory distress syndrome. *N. Engl. J. Med.*, 1987; 317: 1565-70.
49. Veldhuizen RAW, McCaig LA, Akino T, et al. Pulmonary surfactant sub-fractions in patient with the acute respiratory distress syndrome. *Am. J. Respir. Crit. Care Med.*, 1995; 152:1867-71.
50. I lorbarr JO, Soil RF, Sutherland JM, et al. A multicenter randomized placebo. controlled trial of surfactant therapy for respiratory distress syndrome. *N. Engl. J. Med.*, 1989; 320:959-65.
51. Walmrath D, Gunther A, Ghofrani, HA, et al. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. *Am. J. Respir. Crit. Care Med.*, 1996; 154: 57-62.
52. Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. *N. Engl. J. Med.*, 1996; 334: 1417-21.
53. Hartog A, Gommer D, Haitsma JJ, et al. Improvement of lung mechanics by exogenous surfactant : effect of prior application of high positive end -expiratory pressure. *Br. J. Anaesth.*, 2000; 85: 752-6.
54. Hudson LD, Milberg JA, Anardi I). eta!. Clinical risks for development of the acute respiratory distress syndrome. *Am. J. Respir. Crit. Care Med.*, 1995; 151 :293-301.
55. Suchyta MR. Clemmer TP, Elliot CG. et *1. Increased mortality of older patients with acute respiratory distress syndrome. *Chest.*, 1997; III : 1334-39.

56. Krafft P, Fridrich P, Pernerstorfer T, et al. The acute respiratory distress syndrome : definitions, severity and clinical outcome - an analysis of 101 clinical investigations. *Intensive Care Med.*, 1996; 22: 519-29.
57. Montgomery AB, Stager MA, Carrico CJ, et al. Causes of mortality in patients with the adult respiratory distress syndrome. *Am. Rev. Respir. Dis.*, 1985; 132 485-89.
58. Ferring M, Vincent JL, Is outcome from ARDS related to the severity of respiratory failure? *Eur. Respir. J.*, 1997; 10 : 1297-1300.